CF PHARMTECH, INC.

CF PharmTech, Inc.

Equities

2652

CNE1000074R9

Pharmaceuticals

Delayed Hong Kong S.E. Other stock markets 01:52:55 2026-03-09 am EDT			5-day change	1st Jan Change
28.24 ^HKD	-17.09%		-27.13%	-18.80%

09:45pm	CF PharmTech Gets China Approval for Clinical Trial of Allergic Rhinitis Nasal Spray	MT
09:33pm	Cf Pharmtech announces approval of clinical trial application for olopatadine hydrochloride, mometasone furoate monohydrate nasal spray	RE

CF PharmTech to Join Hang Seng Composite Index

Published on 02/16/2026 at 12:23 am EST

MT Newswires

Lock

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

© MT Newswires - 2026

Latest news about CF PharmTech, Inc.

09:45pm	CF PharmTech Gets China Approval for Clinical Trial of Allergic Rhinitis Nasal Spray	MT
09:33pm	Cf Pharmtech announces approval of clinical trial application for olopatadine hydrochloride, mometasone furoate monohydrate nasal spray	RE
Feb. 23	CF PharmTech says NMPA accepted IND application for ICF004	RE
Feb. 23	CF PharmTech Says Chinese Regulators Accept Investigational New Drug Application for ICF004	MT
Feb. 23	CF PharmTech , Inc. Announces Acceptance of Ind Application for ICF004 by the National Medical Products Administration of the People's Republic of China	CI
Feb. 16	CF PharmTech to Join Hang Seng Composite Index	MT
Jan. 29	China Regulator Accepts CF PharmTech's Budesonide Nasal Spray Marketing Application	MT
Jan. 29	CF PharmTech Inc says NMPA accepts marketing authorization application for Budesonide Nasal Spray	RE
Jan. 29	CF PharmTech, Inc. Announces Acceptance of Marketing Authorization Application for Budesonide Nasal Spray by the National Medical Products Administration	CI
Dec. 30	CF PharmTech, Inc. commences an Equity Buyback Plan for 30,222,358 shares, representing 7.34% of its issued share capital, under the authorization approved on December 16, 2025.	CI
Dec. 23	CF PharmTech's Respiratory Drug Project Selected for Jiangsu Innovative Biologics Program	MT
Dec. 23	Cf Pharmtech, Inc. Announces Selection of A Company-Led Project into the 2025 Jiangsu Provincial Major Science and Technology Program	CI
Dec. 17	CF PharmTech says NMPA accepts clinical trial application for olopatadine hydrochloride and mometasone furoate monohydrate nasal spray	RE
Dec. 17	CF PharmTech, Inc. Announces Clinical Trial Application for Olopatadine Hydrochloride and Mometasone Furoate Monohydrate Nasal Spray Accepted by NMPA	CI
Nov. 25	CF PharmTech Launches H-Share Full Circulation Plan; Shares Slip 2%	MT

Chart CF PharmTech, Inc.

Duration

Period

Chart CF PharmTech, Inc.

2652: Dynamic Chart

Company Profile

Employees

574

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

Stock Market
Stock Market News
CF PharmTech to Join Hang Seng Composite Index

SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!

BENEFIT NOW